



## Akerro Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akerro Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 09:45 a.m. P.T. in San Francisco, CA.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at [www.akerotx.com](http://www.akerotx.com). Following the live webcast, an archived replay will be available on the Company's website.

### About Akerro Therapeutics

Akerro Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH/MASH, a disease without any approved therapies. Akerro's lead product candidate, EFX, is currently being evaluated in two ongoing, 96-week Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic NASH/MASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH/MASH (F4 fibrosis, compensated), as well as two Phase 3 clinical trials, the SYNCHRONY *Histology* study in patients with pre-cirrhotic NASH/MASH (F2-F3 fibrosis) and the SYNCHRONY *Real-World* study in patients with NASH/MASH or NAFLD/MASLD. Akerro is headquartered in South San Francisco. Visit [akerotx.com](http://akerotx.com) and follow us on [LinkedIn](#) and [Twitter](#) for more information.

### Investor Contact:

Christina Tartaglia  
Stern Investor Relations, Inc.  
212.362.1200  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

### Media Contact:

Sarah O'Connell  
732.456.0092  
[soconnell@vergescientific.com](mailto:soconnell@vergescientific.com)